Quarterly report pursuant to Section 13 or 15(d)

Issuance of Series A-1 Preferred Stock (Details)

v3.23.2
Issuance of Series A-1 Preferred Stock (Details) - USD ($)
$ / shares in Units, $ in Millions
 6 Months Ended
Mar. 03, 2023
Jun. 30, 2023
Dec. 31, 2022
Issuance of Series A-1 Preferred Stock (Details) [Line Items]      
Preferred stock, shares authorized   9,969,810 10,000,000
Preferred stock, par value (in Dollars per share)   $ 0.001 $ 0.001
Preferred stock, shares issued  
Preferred stock, shares outstanding  
Series A-1 preferred stock, shares issued   30,190 0
Series A-1 preferred stock, shares outstanding   30,190 0
Series A-1 preferred stock 30,190 30,190 0
Aggregate net proceeds (in Dollars) $ 28.0    
Offering expenses (in Dollars) $ 2.2    
Conversion of shares description   (i) shares of common stock of the Company and, if applicable, shares of Series A-2 Preferred Stock, in lieu of Common Stock, (ii) a tranche A warrant to acquire approximately 46,675,940 shares of Series A-3 Preferred Stock (the “Tranche A Warrant”), (iii) a tranche B warrant to acquire approximately 42,432,672 shares of Series A-4 Preferred Stock (the “Tranche B Warrant”), and (iv) a tranche C warrant to acquire approximately 67,892,276 shares of Series A-5 Preferred Stock (the “Tranche C Warrant”, together with the Tranche A Warrant and the Tranche B Warrant, the “Warrants”). The Tranche A warrants for an aggregate exercise price of approximately $25 million are exercisable until 21 days following the Company’s announcement of receipt of FDA approval for Oxylanthanum Carbonate, the Tranche B warrants for an aggregate exercise price of approximately $25 million are exercisable until 21 days following the Company’s announcement of receipt of Transitional Drug Add-On Payment Adjustment (“TDAPA”) approval for Oxylanthanum Carbonate, and the Tranche C Warrant for an aggregate exercise price of approximately $50 million are exercisable until 21 days following four quarters of commercial sales of Oxylanthanum Carbonate following receipt of TDAPA approval.  
Aggregate fair value (in Dollars)   $ 2.8  
Initial carrying value (in Dollars)   $ 25.4  
Annual rate percentage   8.00%  
Annual dividend rate   14.00%  
Accrued dividends (in Dollars)   $ 0.8  
Price per share (in Dollars per share)   $ 26.3  
Conversion of ownership description   (A) the liquidation preference with respect to such share of Series A-1 Preferred Stock, divided by (B) the conversion price, provided that, to the extent the share conversion would cause such Holder’s beneficial ownership to exceed 9.99%, such holder shall receive shares of Series A-2 Preferred Stock in lieu of common stock, on a one-for-one basis, with respect to the number of shares of common stock that exceed 9.99% ownership, (2) a Tranche A Warrant, (3) a Tranche B Warrant, and (4) a Tranche C Warrant.  
Dividents per share (in Dollars per share)   $ 1,000  
Convertible share of common stock   1  
Warrant [Member]      
Issuance of Series A-1 Preferred Stock (Details) [Line Items]      
Warrants offering costs (in Dollars)   $ 0.2  
Series A-1 Preferred Stock [Member]      
Issuance of Series A-1 Preferred Stock (Details) [Line Items]      
Designated shares of preferred stock   30,190  
Warrants offering costs (in Dollars)   $ 2.0  
Annual rate percentage   8.00%  
Series A-2 Preferred Stock [Member]      
Issuance of Series A-1 Preferred Stock (Details) [Line Items]      
Designated shares of preferred stock   1,800,000  
Series A-3 Preferred Stock [Member]      
Issuance of Series A-1 Preferred Stock (Details) [Line Items]      
Designated shares of preferred stock   1,800,000  
Series A-4 Preferred Stock [Member]      
Issuance of Series A-1 Preferred Stock (Details) [Line Items]      
Designated shares of preferred stock   1,800,000  
Series A-5 Preferred Stock [Member]      
Issuance of Series A-1 Preferred Stock (Details) [Line Items]      
Designated shares of preferred stock   3,600,000  
Series A Preferred Stock [Member]      
Issuance of Series A-1 Preferred Stock (Details) [Line Items]      
Preferred stock, par value (in Dollars per share)   $ 0.001